Is Chemed Corp (CHE) overvalued? · P/E 24, rev $2.43B
Chemed Corp (CHE) is a medical care facilities company listed on NYSE.
This page asks whether Chemed Corp (CHE) looks expensive on cached numbers — not a short thesis.
Latest reported CHE revenue for 2024-12-31 was $2.43B. Net income was $302.0M. Revenue was up 7.4% from 2023-12-31 to 2024-12-31. CHE currently screens at market cap $5.79B and trailing P/E 23.8.
CHE currently screens at market cap $5.79B and trailing P/E 23.8. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CHE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CHE stock page for the full model, not this heading.
Not investment advice.